Dr. Miller is a Market Sector Leader in the Mass General Brigham Innovation office.  Dr. Miller has 30 years of experience in the clinical laboratory industry and personalized medicine field including serving as Vice President and Head of Personalized Healthcare and Biomarker Strategy, Portfolio and Alliances for AstraZeneca Pharmaceuticals; Executive Vice President and Chief Technology Officer of MolecularMD; and Vice President and General Manager of Genzyme Analytical Services. Dr. Miller also serves as Chair of the Scientific Advisory Board and is a member of the Board of Directors of the medical device company, Biomarker Strategies. He received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo.  He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.